ARDX stock forecast
Our latest prediction for Ardelyx Inc's stock price was made on the Nov. 28, 2022 when the stock price was at 1.77$.
In the short term (2weeks), ARDX's stock price should underperform the market by -5.55%. During that period the price should oscillate between -11.01% and +8.52%.
In the medium term (3months), ARDX's stock price should outperform the market by 2.02%. During that period the price should oscillate between -33.94% and +34.42%.Get email alerts
Create a solid portfolio with ARDX
About Ardelyx Inc
Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.
At the moment the company generates 17M USD in revenues.
On its last earning announcement, the company reported a loss of -0.85$ per share.
The book value per share is 2.63$
Three months stock forecastNov. 28, 2022
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|